TScan Therapeutics (TCRX) Return on Capital Employed (2021 - 2026)
TScan Therapeutics (TCRX) posted quarterly Return on Capital Employed of 65.86% for Q1 2026, down 2249.0% year-over-year from 3.06% in Q1 2025, and down 9.99% quarter-over-quarter from 59.88% in Q4 2025.
TScan Therapeutics (TCRX) Return on Capital Employed (2021 - 2026) Analysis & Trends
TScan Therapeutics (TCRX) has reported Return on Capital Employed for 6 consecutive years, with 65.86% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed fell 2249.0% year-over-year to 65.86%; the TTM figure through Mar 2026 stood at 65.86% (down 2249.0% YoY), while the FY2025 annual figure was 48.29%, down 109.0% from the prior year.
- Return on Capital Employed retreated to 65.86% in Q1 2026 per TCRX's latest filing, from 59.88% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 33.49% in Q3 2023 and bottomed at 65.86% in Q1 2026.
- Historically, Return on Capital Employed has averaged 44.61% across 5 years, with a median of 42.5% in 2023.
- Annual changes were most pronounced in 2023 — Return on Capital Employed jumped 1020 bps — and 2025, when it sank 2329 bps.
- TScan Therapeutics' Return on Capital Employed stood at 40.39% in 2022, then rose by 8 bps to 37.09% in 2023, then dropped by 12 bps to 41.66% in 2024, then sank by 44 bps to 59.88% in 2025, then slipped by 10 bps to 65.86% in 2026.
- Business Quant data shows TCRX's Return on Capital Employed at 65.86% in Q1 2026, 59.88% in Q4 2025, and 59.19% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | TScan Therapeutics | 100.62 Mn | 100.62 Mn | - | -77.39% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -77.39% |
| Mar 31, 2026 | -65.86% |
| Dec 31, 2025 | -59.88% |
| Sep 30, 2025 | -59.19% |
| Jun 30, 2025 | -50.73% |
| Mar 31, 2025 | -43.37% |
| Dec 31, 2024 | -41.66% |
| Sep 30, 2024 | -35.90% |
| Jun 30, 2024 | -41.44% |
| Mar 31, 2024 | -45.37% |
| Dec 31, 2023 | -37.09% |
| Sep 30, 2023 | -33.49% |
| Jun 30, 2023 | -39.30% |
| Mar 31, 2023 | -42.50% |
| Dec 31, 2022 | -40.39% |
| Sep 30, 2022 | -43.69% |
| Jun 30, 2022 | -42.93% |
| Mar 31, 2022 | -35.62% |
| Dec 31, 2021 | -27.77% |
| Sep 30, 2021 | -29.24% |